Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen)

References

• Nandi S, Kumar M. Development in Immunoprophylaxis against Rabies for Animals and Humans. Avicenna journal of medical biotechnology 2010; 2:3-21; PMID:23407587
   PubMedGoogle Scholar
• (WHO) WHO. Rabies Vaccines: WHO position paper. Weekly epidemiological record 2010; 32:309-20; PMID:18064757
   PubMedGoogle Scholar
• Menezes R. Rabies in India. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2008; 178:564-6; PMID:18299543; http://dx.doi.org/10.1503/cmaj.071488
   PubMed Web of Science ®Google Scholar
• Hemachudha T, Wacharapluesadee S, Mitrabhakdi E, Wilde H, Morimoto K, Lewis RA. Pathophysiology of human paralytic rabies. Journal of neurovirology 2005; 11:93-100; PMID:15804967; http://dx.doi.org/10.1080/13550280590900409
   PubMed Web of Science ®Google Scholar
• Gadre G, Satishchandra P, Mahadevan A, Suja MS, Madhusudana SN, Sundaram C, Shankar SK. Rabies viral encephalitis: clinical determinants in diagnosis with special reference to paralytic form. Journal of neurology, neurosurgery, and psychiatry 2010; 81:812-20; PMID:19965838; http://dx.doi.org/10.1136/jnnp.2009.185504
   PubMedGoogle Scholar
• WHO. WHO prequalified vaccines. 2012.
   Google Scholar
• Ministry of Health & Family Welfare GoI. National Guidelines for Rabies Prophylaxis and Intra-dermal Administration of Cell Culture Rabies Vaccines. 2007
   Google Scholar
• Ichhpujani RL, Chhabra M, Mittal V, Bhattacharya D, Singh J, Lal S. Knowledge, attitude and practices about animal bites and rabies in general community–a multi-centric study. The Journal of communicable diseases 2006; 38:355-61; PMID:17913213
   PubMedGoogle Scholar
• Baxter JM. One in a million, or one in thousand: What is the morbidity of rabies in India? Journal of global health 2012; 2:010303; PMID:23198128; http://dx.doi.org/10.7189/jogh.01.010303
   PubMedGoogle Scholar
• Chutivongse S, Wilde H, Fishbein DB, Baer GM, Hemachudha T. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 1991; 9:573-6; PMID:1771970; http://dx.doi.org/10.1016/0264-410X(91)90244-Z
   PubMed Web of Science ®Google Scholar
• Colnot F, Sureau P, Alexandre JL, Arnaudo JP, Hesse JY, Jeanmaire H. [Post-exposure antirabies vaccination. Early serological response to vaccine cultivated on VERO cells using a reduced 2-1-1 schedule]. Presse Med 1994; 23:1609-12; PMID:7831241
   PubMed Web of Science ®Google Scholar
• Liu H, Huang G, Tang Q, Li J, Cao S, Fu C, Cao Q, Liu B, Pan H, Wang M. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Human vaccines 2011; 7:220-4; PMID:21311216; http://dx.doi.org/10.4161/hv.7.2.14003
   PubMed Web of Science ®Google Scholar
• WHO. Rabies Vaccines: WHO Position Paper. 2010
   Google Scholar
• Sudarshan MK, Narayana DH, Madhusudana SN, Holla R, Ashwin BY, Gangaboraiah B, Ravish HS. Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India. Human vaccines & immunotherapeutics 2012; 8:1077-81; PMID:22699446; http://dx.doi.org/10.4161/hv.20471
   PubMed Web of Science ®Google Scholar
• Zalan E, Wilson C, Pukitis D. A microtest for the quantitation of rabies virus neutralizing antibodies. Journal of biological standardization 1979; 7:213-20; PMID:387798; http://dx.doi.org/10.1016/S0092-1157(79)80024-4
   PubMedGoogle Scholar
• Moore SM, Hanlon CA. Rabies-specific antibodies: measuring surrogates of protection against a fatal disease. PLoS neglected tropical diseases 2010; 4:e595; PMID:20231877; http://dx.doi.org/10.1371/journal.pntd.0000595
   PubMed Web of Science ®Google Scholar
• Wunner WH, Jackson AC. Rabies: Scientific Basis of the Disease and Its Management. Academic Press, 2010
   Google Scholar
• Vodopija I, Sureau P, Lafon M, Baklaic Z, Ljubicic M, Svjetlicic M, Smerdel S. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine 1986; 4:245-8; PMID:3541428; http://dx.doi.org/10.1016/0264-410X(86)90138-6
   PubMed Web of Science ®Google Scholar
• (WHO) WHO. WHO Expert Committee on Rabies. WHO Technical Report 1992: 1-84.
   Google Scholar
• Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett S, Levis R, Meltzer MI, Schaffner W, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009; 27:7141-8; PMID:19925944; http://dx.doi.org/10.1016/j.vaccine.2009.09.029
   PubMed Web of Science ®Google Scholar
• Vodopija I, Baklaic Z, Vodopija R. Rabipur: a reliable vaccine for rabies protection. Vaccine 1999; 17:1739-41; PMID:10194832; http://dx.doi.org/10.1016/S0264-410X(98)00427-7
   PubMed Web of Science ®Google Scholar
• Vodopija I, Sureau P, Smerdel S, Lafon M, Baklaic Z, Ljubicic M, Svjetlicic M. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine 1988; 6:283-6; PMID:3420976; http://dx.doi.org/10.1016/0264-410X(88)90225-3
   PubMed Web of Science ®Google Scholar
• Lang J, Simanjuntak GH, Soerjosembodo S, Koesharyono C. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Bulletin of the World Health Organization 1998; 76:491-5; PMID:9868840
   PubMed Web of Science ®Google Scholar
• Huang G, Liu H, Tang Q, Yu P, Shen X, Zhang Y, Liu X, Cao Q, Fu C, Liu B, et al. Making rabies prophylaxis more economical: Immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers. Human vaccines & immunotherapeutics 2013; 10:1, 114-19; PMID:24008819; http://dx.doi.org/10.4161/hv.26264
   PubMedGoogle Scholar
• Kulkarni PS, Sapru A, D'Costa PM, Pandit A, Madhusudana SN, Yajaman AB, Mangrule S, Gunale B, Bavdekar AR. Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers. Vaccine 2013; 31:2719-22; PMID:23583817; http://dx.doi.org/10.1016/j.vaccine.2013.03.050
   PubMed Web of Science ®Google Scholar